Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CCNC | P24863 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600309 | 0.91 | CDK8 (0.82) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25729256 | 0.89 | CDK8 (0.62) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25793170 | 0.89 | MAPK13 (0.74) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL19303194 | 0.87 | CDK8 (1.00) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15946922 | 0.87 | CDK8 (0.76) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL18744685 | 0.87 | CDK8 (0.76) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13791346 | 0.86 | MAPK14 (0.79) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL19669083 | 0.85 | CDK8 (0.72) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13741201 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL20376321 | 0.84 | MAPK14 (0.57) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | TOPIVERT PHARMA LTD. (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9624196-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9447076-B2 | Inhibitor of p38 map kinase | RESPIVERT LTD. (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-8202899-B2 | Pyrazole urea derivatives used as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAP3K1 | CDK8 390/4885MAPK14 5/4885MAPK13 4/4885 |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | CDK8 66/4885MAPK14 113/4885MAPK13 199/4885 |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPK4, MAPK8 | CDK8 681/4885MAPK14 13/4885MAPK13 10/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | CDK8 66/4885MAPK14 113/4885MAPK13 199/4885 |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | CDK8 477/4885MAPK14 9/4885MAPK13 16/4885 |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | MAP3K1, MAP3K19, MAP3K13 | CDK8 117/4885MAPK14 105/4885MAPK13 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.